Wolff M

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Mertens LJ, Betzler F, Brand M +24

PreprintPsilocybin

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”

Wolff M, Kangaslampi S, Zeifman R +1

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

Mertens LJ, Koslowski M, Betzler F +23

Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study.

Evens R, Uyar A, Gosslau E +4

PreprintPsilocybin

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”

Wolff M, Kangaslampi S, Zeifman R +1

Therapeutic-Like Context and Relational Support During Psychedelic Use Moderate Links Among Stress, Challenging Experiences, and Psychological Outcomes.

Cherniak AD, Granqvist P, Mikulincer M +1

Safety and efficacy are hardly separable in psychedelic therapy: A mechanism-based critique.

Wolff M, Aicher HD

Questioning the recovery of dissociated traumatic memories under psilocybin: comment on "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa".

Kangaslampi S, Wolff M, Doss MK +2

Pharmacodynamic biomarker - or psychotherapeutic process? Comment on "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression".

Wolff M, Kangaslampi S

PreprintPsychedelics

Therapeutic Context and Support during Psychedelic Use Moderate Links among Stress, Challenging Experiences, and Psychological Outcomes

Cherniak AD, Granqvist P, Mikulincer M +1

Common factors in altered states: Understanding psychedelic therapy through the lens of Grawe's general change mechanisms.

Wolff M, Rutrecht H, Mertens LJ +6

Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.

Muthumaraswamy SD, Baggott MJ, Schenberg EE +4

Key competencies for psychedelic treatment in real-world mental health care settings.

Wolff M, Rutrecht H, Gründer G +2

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

[Acceptance of psilocybin-assisted therapy in German-speaking countries].

Hartter N, Däumichen M, Schmidt C +3

Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).

Wolff M, Evens R, Mertens LJ +6

Europe PMC2024

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.

Mertens LJ, Koslowski M, Betzler F +9

Europe PMC2022

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.

Wolff M, Mertens LJ, Walter M +2

Europe PMC2022